Canaccord lowered the firm’s price target on Enovix to $17 from $22 and keeps a Buy rating on the shares. The firm said the earnings call provided comments on its strategic realignment, acquisition closing, and factory acceptance testing (FAT) updates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ENVX:
- Enovix says tests show its cells ‘outperformed all competitive cells’
- Enovix sees FY23 operational cash use of $110M, capex of $65M
- Enovix sees Q4 revenue $3M-$4M, consensus $530K
- Enovix reports Q3 non-GAAP EPS (19c), consensus (23c)
- Enovix Batteries Demonstrate Highest Energy Density Among Cells Evaluated According to Polaris Battery Labs